Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Licenses MEDI2070, As AstraZeneca Continues Non-Core Exits

Executive Summary

Continuing its strategy to exit non-core activities, AstraZeneca's licensed Allergan global rights to its IL-23 monoclonal antibody in Phase IIb testing for moderate-to-severe Crohn’s disease and ready for Phase II studies in ulcerative colitis. Analysts say the deal makes sense for both parties.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q4 2016
Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel